Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-05
2008-12-02
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S469000, C548S492000, C548S493000, C514S415000
Reexamination Certificate
active
07459478
ABSTRACT:
Compounds of formula (I) and II) are providedwherein: X is an alkali metal or a basic amine moiety; R1is alkyl, cycloalkyl, —CH2-cycloalkyl, pyridinyl, —CH2-pyridinyl, phenyl or benzyl, the rings of these groups being optionally substituted; R2is H, halogen, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, —CH2-cycloalkyl, —NH2, or —NO2; R3is phenyl, benzyl, benzyloxy, pyridinyl, or —CH2-pyridinyl, with the rings of these groups being optionally substituted; or a pharmaceutically acceptable salt or ester form thereof, as well as pharmaceutical compositions and methods using these compounds as inhibitors of plasminogen activator inhibitor-1 (PAI-1) and as therapeutic compositions for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis.
REFERENCES:
patent: 3026325 (1962-03-01), Heinzelman et al.
patent: 3476770 (1969-11-01), Scherrer
patent: 3557142 (1971-01-01), Bell
patent: 3843683 (1974-10-01), Bell
patent: 4478819 (1984-10-01), Hercelin et al.
patent: 4736043 (1988-04-01), Michel et al.
patent: 4851406 (1989-07-01), Mertens et al.
patent: 5164372 (1992-11-01), Matsuo et al.
patent: 5420289 (1995-05-01), Musser et al.
patent: 5482960 (1996-01-01), Berryman
patent: 5502187 (1996-03-01), Ayer et al.
patent: 5541343 (1996-07-01), Himmelsbach et al.
patent: 5612360 (1997-03-01), Boyd et al.
patent: 5859044 (1999-01-01), Dow et al.
patent: 6048875 (2000-04-01), De Nanteuil et al.
patent: 6110963 (2000-08-01), Malamas
patent: 6166069 (2000-12-01), Malamas et al.
patent: 6232322 (2001-05-01), Malamas et al.
patent: 6251936 (2001-06-01), Wrobel et al.
patent: 6302837 (2001-10-01), De Nanteuil et al.
patent: 6479524 (2002-11-01), Priepke et al.
patent: 6599929 (2003-07-01), Cho et al.
patent: 6787556 (2004-09-01), Hargreaves et al.
patent: 6800645 (2004-10-01), Cox et al.
patent: 6800654 (2004-10-01), Mayer et al.
patent: 6844358 (2005-01-01), Malamas et al.
patent: 7074817 (2006-07-01), Elokdah et al.
patent: 7101903 (2006-09-01), Elokdah et al.
patent: 2003/0013732 (2003-01-01), Elokdah
patent: 2003/0018067 (2003-01-01), Elokdah et al.
patent: 2003/0060497 (2003-03-01), Gerlach
patent: 2003/0125371 (2003-07-01), Elokdah et al.
patent: 2004/0116488 (2004-06-01), Jennings et al.
patent: 2004/0116504 (2004-06-01), Elokdah et al.
patent: 2004/0122070 (2004-06-01), Jennings
patent: 2004/0138283 (2004-07-01), Jennings et al.
patent: 2004/0204417 (2004-10-01), Perez et al.
patent: 2005/0070584 (2005-03-01), Havran et al.
patent: 2005/0070585 (2005-03-01), Elokdah et al.
patent: 2005/0070587 (2005-03-01), Elokdah et al.
patent: 2005/0070592 (2005-03-01), Gundersen
patent: 2005/0096377 (2005-05-01), Hu
patent: 2005/0113428 (2005-05-01), Gopalsamy et al.
patent: 2005/0113438 (2005-05-01), Hu et al.
patent: 2005/0113439 (2005-05-01), Hu
patent: 2005/0119296 (2005-06-01), Elokdah et al.
patent: 2005/0119326 (2005-06-01), Havran et al.
patent: 2005/0119327 (2005-06-01), Hu
patent: 2005/0215626 (2005-09-01), Havran et al.
patent: 3147276 (1983-06-01), None
patent: 43 38 770 (1995-05-01), None
patent: 19543639 (1997-05-01), None
patent: 19753522 (1999-06-01), None
patent: 0 416 609 (1991-03-01), None
patent: 0 508 723 (1992-10-01), None
patent: 0 512 570 (1992-11-01), None
patent: 0 540 956 (1993-05-01), None
patent: 0 655 439 (1995-05-01), None
patent: 0 759 434 (1997-02-01), None
patent: 0 819 686 (1998-01-01), None
patent: 0 822 185 (1998-02-01), None
patent: 0 955 299 (1999-11-01), None
patent: 1 092 716 (2001-04-01), None
patent: 1 156 045 (2001-11-01), None
patent: 2 244 499 (1975-04-01), None
patent: 2 777 886 (1999-10-01), None
patent: 2 799 756 (2001-04-01), None
patent: 1 321 433 (1973-06-01), None
patent: 94/13637 (1994-06-01), None
patent: 94/14434 (1994-07-01), None
patent: 94/26738 (1994-11-01), None
patent: 95/10513 (1995-04-01), None
patent: 96/06840 (1996-03-01), None
patent: 96/21656 (1996-07-01), None
patent: 96/26207 (1996-08-01), None
patent: 96/32379 (1996-10-01), None
patent: 97/09308 (1997-03-01), None
patent: 97/43260 (1997-11-01), None
patent: 97/48697 (1997-12-01), None
patent: 98/08818 (1998-03-01), None
patent: 99/28297 (1999-06-01), None
patent: 99/43651 (1999-09-01), None
patent: 99/43654 (1999-09-01), None
patent: 99/43672 (1999-09-01), None
patent: 99/46260 (1999-09-01), None
patent: 99/50268 (1999-10-01), None
patent: 99/58519 (1999-11-01), None
patent: 99/61435 (1999-12-01), None
patent: 00/32180 (2000-06-01), None
patent: 00/35919 (2000-06-01), None
patent: 00/46195 (2000-08-01), None
patent: 00/46197 (2000-08-01), None
patent: 00/64876 (2000-11-01), None
patent: 00/64888 (2000-11-01), None
patent: 01/12187 (2001-02-01), None
patent: 02/030895 (2002-04-01), None
patent: 02/072549 (2002-09-01), None
patent: 03/000253 (2003-01-01), None
patent: 03/031409 (2003-04-01), None
patent: 03/068742 (2003-08-01), None
patent: 03/087087 (2003-10-01), None
patent: 2004/052854 (2004-06-01), None
Elokdah et al (2003): STN International HCAPLUS database, (Columbus, Ohio), Accession No. 2003:5772.
U.S. Appl. No. 10/947,710, filed Sep. 23, 2004, Commons et al.
U.S. Appl. No. 10/947,711, filed Sep. 23, 2004, Gopalsamy et al.
U.S. Appl. No. 11/208,772, filed Aug. 22, 2005, Commons.
U.S. Appl. No. 11/208,775, filed Aug. 22, 2005, Commons et al.
U.S. Appl. No. 11/208,777, filed Aug. 22, 2005, Commons et al.
Aggarwal et al., “A catalytic antibody programmed for torsional activation of amide bond hydrolysis,”Chem. Eur. J., Jan. 25, 2003, 9(13), 3132-3142.
Aznar, J. et al.,Haemostasis, 1994, 24, 243-251.
Ballantine, J. A., “The Chemistry of Bacteria,”Journal of the Chemical Society Abstracts, 1957, 2222-2227.
Biemond, B.J. et al.,Circulation, 1995, 91(4), 1175-1181.
Carmeliet, P. et al.,J. Clin. Investigations, 1993, 92, 2756-2760.
Charlton, Peter, “Status of plasminogen activator inhibitor-1 as a therapeutic target,”Expert Opinion On Investigational Drugs, May 1997, 6(5), 539-554.
Crandall, D. L. et al., “Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy,”Journal of Thrombosis and Haemostasis, Mar. 17, 2004, 2, 1422-1428.
Da Settimo, A. et al., “Reaction of indole derivatives with bromine, substitution, oxidation, and dimerization,”J Org Chem, 1970, 35(8), 2546-2551.
Daci, E. et al.,Bone and mineral Research, 2000, 15(8), 1510-1516.
Delgado et al.,Journal of Organic Chemistry, 1993, 58(10), 2862-2866.
Dillard R. D. et al., “Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A21. Indole-3-Acetamides”,Journal of Medicinal Chemistry, American Chemical Society, 1996, 39(26), 5119-5136.
Guzzo, P.R. et al., “Synthesis of a conformationally constrained threonin-valine dipeptide mimetic: design of a potential inhibitor of plasminogen activator inhibitor-1,”Tetrahedron Letters, 2002, 43(1), 41-43.
Hipskind, P. A. et al., “Potent and selective 1,2,3-trisubstituted indole NPY Y-1 antagonists,”J Med Chem, 1997, 40(23), 3712-3714.
Julia et al., CA 57:49169, 1962.
Krishnamutri, C. et al.,Blood, Mar. 1987, 69(3), 793-803.
Levi, M. et al.,Circulation, Jan. 1992, 85(1), 305-312.
Malamas, M. S. et al., “Antihyperglycemic activity of new 1,2,4-oxadiazolidine-3,5-diones,”Eur. J. Med. Chem., 2001, 36, 31-42.
Malamas, M.S. et al. “Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy,”Journal of Medicinal Chemistry, 2000, 43(7), 1293-1310.
Malamas, M.S. et al. “Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties,”Journal of Medicinal Chemistry, Apr. 6, 2000, 43(7), 1293-1310.
Moody et al., CA 120:298300, 1994.
Nordt, T. et al.,J. Clin. Endocrinology and Metabolism, 2000, 85(4), 1563-1568.
Reilly, C. et al.,Arterioscelrosis and Thrombosis, Sep./Oct. 1991, 11(5), 1276-1286.
Rocha, E. et al.,Fibrinolysis, 1994, 8, 294-3
Elokdah Hassan Mahmound
Li David Zenan
Kurlandsky David
Larsen Scott
Ng Mabel
Shameem Golam M
Wyeth
LandOfFree
Substituted dihydropyrano indole-3,4-dione derivatives as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted dihydropyrano indole-3,4-dione derivatives as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted dihydropyrano indole-3,4-dione derivatives as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4038332